by dyadic | Mar 28, 2024 | Press Releases
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibody response for DYAI-100 a recombinant protein...
by dyadic | Mar 28, 2024 | Press Releases
JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale...
by dyadic | Mar 27, 2024 | Press Releases
JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for...
by dyadic | Mar 26, 2024 | Press Releases
The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO. JUPITER, Fla., March 26, 2024 (GLOBE NEWSWIRE) — Dyadic...
by dyadic | Mar 21, 2024 | Press Releases
JUPITER, Fla., March 21, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for...
by dyadic | Mar 14, 2024 | Press Releases
JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building innovative...
